Ridaforolimus (Deforolimus, MK-8669)

Ridaforolimus (Deforolimus, MK-8669) は、0.2nMのIC50による選択的なmTOR阻害剤です。

4 5 1レビュー 3製品表彰状
価格 在庫  
USD 88 In stock
USD 151 In stock
USD 302 In stock
USD 466 In stock
USD 970 In stock

Ridaforolimus (Deforolimus, MK-8669) 化学構造
分子量: 990.21



Quality Control & MSDS


  • Combination Therapy
  • Compare mTOR Inhibitors
  • 研究分野



情報 Ridaforolimus (Deforolimus, MK-8669) は、0.2nMのIC50による選択的なmTOR阻害剤です。
目標 mTOR
IC50 0.2 nM [1]
In vitro試験 Treatment of HT-1080 cells with Deforolimus induces a dose-dependent inhibition of phosphorylation of both S6 and 4E-BP1, with IC50 of 0.2 nM and 5.6 nM, respectively, and leads to a decrease in cell size, an increase in the proportion of cells in the G1 phase of the cell cycle, and inhibition of glucose uptake. Deforolimus displays significant antiproliferative activity a broad panel of cell lines with EC50 of 0.2-2.3 nM. Deforolimus potently and selectively inhibits VEGF production in a dose-dependent manner. [1] Deforolimus treatment significantly induces growth suppression in human NSCLC cell lines with IC30 values of 2.45-8.83 nM, with the exception of H157 with IC30 of >20 nM. Deforolimus treatment (2.8-5.9 nM) significantly dephosphorylates p70S6KThr389 in A549, H1703 and H157 cells, except H1666 that may express a resistant variant of mTORC1, and causes increased phosphorylation of pAKTser473 and pAKTThr308 in A549 and H1703 cells. Deforolimus in combination with the MEK inhibitors, CI-1040 or PD0325901 exhibits dose-dependent synergism in lung cancer cell lines, which is associated with the suppression of proliferation rather than enhancement of cell death, involving the inhibition of ribosomal biogenesis by 40% within 24 hours and a decreased polysome/monosome ratio. [2]
In vivo試験 Administration of Deforolimus exerts significant antitumor effects in mice bearing PC-3 (prostate), HCT-116 (colon), MCF7 (breast), PANC-1 (pancreas) or A549 (lung) xenografts in a dose-dependent manner, and inhibits mTOR signaling in in SK-LMS-1 xenograft model associated with inhibition of tumor growth. [1]

推薦された実験操作 (公開の文献だけ)

キナーゼアッセイ: [1]

Cell based target inhibition HT-1080 cells are treated with increasing concentrations of Deforolimus (0-100 nM) for 2 hours, prior to harvest. Cellular lysates are extracted in denaturing lysis buffer, resolved on SDS-PAGE and transferred to PVDF membranes. After blocking, membranes are incubated with primary antibodies for 1 hour, followed by appropriate HRPconjugated secondary antibodies for 1 hour at room temperature. Immunoreactive proteins are detected using enhanced chemiluminescence and autoradiography performed by exposure to X-ray film. IC50 is determined from the inhibition of levels of phosphorylated ribosomal protein S6 (p-S6) and 4E-BP1 (p-4E-BP1).

細胞アッセイ: [2]

細胞系 Colo205, H1755, H1395, H1666, A549, H157, and H1703 cells
濃度 Dissolved in ethanol, final concentrations ~ 1 μM
処理時間 72-120 hours
方法 Cells are seeded at 2-3 × 104/mL, and serial dilutions of Deforolimus are added after 2 hours, for at least three cell doublings (72-120 hours). Deforolimus effects are measured using the CellTiter 96 Aqueous nonradioactive cell proliferation assay and Sulforhodamine B assays. For Deforolimus, growth effects are described as IC30 because rapamycin and its derivatives do not significantly impede cell proliferation.

動物実験: [1]

動物モデル Male and female athymic NCr-nu mice with xenografts established by subcutaneous implantation of PC-3, A549, HCT-116, MCF7, PANC-1 and SK-LMS-1 tumors
製剤 Dissolved in ethanol, and diluted in a vehicle of 4% ethanol, 5% Tween 80, and 5% propylene glycol
投薬量 ~10 mg/kg
管理 Intraperitoneally



Download Ridaforolimus (Deforolimus, MK-8669) SDF
分子量 990.21


CAS No. 572924-54-0
別名 AP23573
溶解度 (25°C)
  • DMSO 198 mg/mL
  • 水 <1 mg/mL
  • エタノール <1 mg/mL
保管 2年 -20°C
6月-80°Cin DMSO


カスタマーレビュー (1)

Click to enlarge
Source Dr. Zhang of Tianjin Medical University. Ridaforolimus (Deforolimus, MK-8669) purchased from Selleck
Method Western blotting
Cell Lines Breast cancer cells
Concentrations 0-5 nM
Incubation Time 24 h
Results Deforolimus treatment resulted in a reduction of mTOR phosphorylation in Breast cancer cells.

製品表彰状 (3)

  • Rapamycin allosterically inhibits the proteasome. [Osmulski PA, et al. Mol Pharmaco 2013;84(1):104-13]

    PubMed: 23619386
  • Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease. [Ashe KM, et al. Mol Genet Meta 2010;100(4):309-15]

    PubMed: 20554235
  • Activation of mammalian target of rapamycin contributes to pain nociception induced in rats by BmK I, a sodium channel-specific modulator. [Jiang F, et al. Neurosci Bull 2013;10.1007/s12264-013-1377-0]

    PubMed: 24132796



電話番号: +1-832-582-8158 Ext:3月曜日〜金曜日 9:00 AM–5:00 PM (米国中部標準時)


* 必須

Related mTOR 阻害剤

  • BEZ235 (NVP-BEZ235, Dactolisib)

    BEZ235 (NVP-BEZ235, Dactolisib)は競争性的なPI3K、mTOR 阻害剤、 p110α, p110γ, p110δ と p110β を作用すると、 IC50 がぞれぞれ 4 nM, 5 nM, 7 nM と 75 nMになる.

  • PI-103

    PI-103は、強力な、細胞透過性、ATP競争的クラスI PI3K阻害剤で、DNA-PK、 p110α、 mTORC1、 PI3-KC2β、 p110δ、 mTORC2、 p110β、p110γ に作用すると、IC50 がそれぞれ 2 nM、 8 nM、 20 nM、26 nM、 48 nM、 83 nM、 88 nM 、150 nMになる。

  • Rapamycin (Sirolimus)

    Rapamycin (Sirolimus) は、特定のmTOR阻害剤で、IC50 が ~0.1 nMです。

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864)は、特定のmTOR阻害剤で、IC50 が 1.76 μM。

  • Everolimus (RAD001)

    Everolimus (RAD001) は、1.6-2.4nMのIC50によるFKBP12のmTOR阻害剤です。

  • KU-0063794


  • WYE-354

    WYE-354は、mTORへの強力で、特定で、ATP競争的阻害剤で 、IC50 が 5 nMになる。

  • GSK1059615

    GSK1059615は、ホスホイノシチド3-キナーゼ(PI3Kα、β、δとγ)とラパマイシン(mTOR)の哺乳類の標的の小説と二重阻害剤で 、IC50 が 0.4-12 nMになる。

  • SAR245409 (XL765)

    SAR245409 (XL765)は、mTOR/PI3kの二重阻害剤で、mTOR、 p110α、 p110β、 p110γ 、p110δに作用すると、 IC50 がそれぞれ 157 nM、39 nM、 113 nM、 9 nM 、43 nMになる。

  • AZD8055



Tags: Ridaforolimus (Deforolimus, MK-8669)を買う | Ridaforolimus (Deforolimus, MK-8669)供給者 | Ridaforolimus (Deforolimus, MK-8669)を購入する | Ridaforolimus (Deforolimus, MK-8669)費用 | Ridaforolimus (Deforolimus, MK-8669)生産者 | オーダーRidaforolimus (Deforolimus, MK-8669) | Ridaforolimus (Deforolimus, MK-8669)代理店